

SAFETY DATA SHEET



Insulin Glargine Formulation

Version
5.1

Revision Date:
30.09.2023

SDS Number:
45327-00026

Date of last issue: 04.04.2023
Date of first issue: 07.01.2015

SECTION 1. IDENTIFICATION

Product name : Insulin Glargine Formulation

Manufacturer or supplier's details

Company : MSD

Address : 855 Leandro N. Alem St., 8 Floor
Buenos Aires, Argentina C1001AFB

Telephone : 908-740-4000

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification

Acute toxicity (Oral) : Category 5

Skin corrosion/irritation : Category 2

Serious eye damage/eye irritation : Category 1

Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Blood, Nervous system)

Short-term (acute) aquatic hazard : Category 3

GHS label elements

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H303 May be harmful if swallowed.
H315 Causes skin irritation.
H318 Causes serious eye damage.
H373 May cause damage to organs (Blood, Nervous system)

SAFETY DATA SHEET



Insulin Glargine Formulation

Version 5.1	Revision Date: 30.09.2023	SDS Number: 45327-00026	Date of last issue: 04.04.2023 Date of first issue: 07.01.2015
----------------	------------------------------	----------------------------	-------------------------------------------------------------------

through prolonged or repeated exposure if swallowed.
H402 Harmful to aquatic life.

Precautionary Statements

: **Prevention:**

P260 Do not breathe dust.
P264 Wash skin thoroughly after handling.
P273 Avoid release to the environment.
P280 Wear protective gloves/ eye protection/ face protection.

: **Response:**

P302 + P352 IF ON SKIN: Wash with plenty of water.
P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/ doctor.
P312 Call a POISON CENTER/ doctor if you feel unwell.
P332 + P313 If skin irritation occurs: Get medical advice/ attention.
P362 + P364 Take off contaminated clothing and wash it before reuse.

: **Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Insulin Glargine	160337-95-1	>= 90 -<= 100
m-Cresol	108-39-4	>= 3 -< 5

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention if symptoms occur.

In case of skin contact : In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : In case of contact, immediately flush eyes with plenty of water

SAFETY DATA SHEET



Insulin Glargine Formulation

Version 5.1	Revision Date: 30.09.2023	SDS Number: 45327-00026	Date of last issue: 04.04.2023 Date of first issue: 07.01.2015
----------------	------------------------------	----------------------------	-------------------------------------------------------------------

If swallowed	for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention immediately.
Most important symptoms and effects, both acute and delayed	: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water. May be harmful if swallowed. Causes skin irritation. Causes serious eye damage. May cause damage to organs through prolonged or repeated exposure if swallowed.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	: Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire fighting	: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Carbon oxides
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	: Sweep up or vacuum up spillage and collect in suitable container for disposal.

SAFETY DATA SHEET



Insulin Glargine Formulation

Version
5.1

Revision Date:
30.09.2023

SDS Number:
45327-00026

Date of last issue: 04.04.2023
Date of first issue: 07.01.2015

Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures	: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation	: Use only with adequate ventilation.
Advice on safe handling	: Do not get on skin or clothing. Do not breathe dust. Do not swallow. Do not get in eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Keep container tightly closed. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.
Conditions for safe storage	: Keep in properly labeled containers. Keep tightly closed. Store in accordance with the particular national regulations.
Materials to avoid	: Do not store with the following product types: Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Insulin Glargine	160337-95-1	TWA	3 µg/m ³ (OEB 4)	Internal
m-Cresol	108-39-4	CMP	5 ppm	AR OEL
	Further information: Skin			
		TWA (Inhalable fraction and	20 mg/m ³	ACGIH

SAFETY DATA SHEET



Insulin Glargine Formulation

Version 5.1 Revision Date: 30.09.2023 SDS Number: 45327-00026 Date of last issue: 04.04.2023
Date of first issue: 07.01.2015

		vapor)	
--	--	--------	--

Engineering measures	: Ensure adequate ventilation, especially in confined areas. Minimize workplace exposure concentrations. Apply measures to prevent dust explosions. Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).
Personal protective equipment	
Respiratory protection	: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	: Combined particulates and organic vapor type
Hand protection	
Material	: Chemical-resistant gloves
Remarks	: Choose gloves to protect hands against chemicals depending on the concentration specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.
Eye protection	: Wear the following personal protective equipment: Chemical resistant goggles must be worn. If splashes are likely to occur, wear: Face-shield
Skin and body protection	: Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential. Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).
Hygiene measures	: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	: Crystalline powder
Color	: white
Odor	: No data available
Odor Threshold	: No data available
pH	: No data available
Melting point/freezing point	: No data available

SAFETY DATA SHEET



Insulin Glargine Formulation

Version 5.1 Revision Date: 30.09.2023 SDS Number: 45327-00026 Date of last issue: 04.04.2023 Date of first issue: 07.01.2015

Initial boiling point and boiling range : No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : No data available

Relative vapor density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-octanol/water : No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

SAFETY DATA SHEET



Insulin Glargine Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023
5.1 30.09.2023 45327-00026 Date of first issue: 07.01.2015

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

May be harmful if swallowed.

Product:

Acute oral toxicity	: Acute toxicity estimate: 3.025 mg/kg Method: Calculation method
Acute dermal toxicity	: Acute toxicity estimate: > 5.000 mg/kg Method: Calculation method

Components:

Insulin Glargine:

Acute oral toxicity : Remarks: No data available

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

m-Cresol:

Acute oral toxicity	: LD50 (Rat): 121 mg/kg Remarks: Based on data from similar materials
Acute inhalation toxicity	: Assessment: Corrosive to the respiratory tract.
Acute dermal toxicity	: LD50 (Rabbit): 301 mg/kg Remarks: Based on data from similar materials

Skin corrosion/irritation

Causes skin irritation.

Components:

Insulin Glargine:

Remarks : No data available

m-Cresol:

Species : Rabbit
Result : Corrosive after 3 minutes to 1 hour of exposure

SAFETY DATA SHEET



Insulin Glargine Formulation

Version
5.1

Revision Date:
30.09.2023

SDS Number:
45327-00026

Date of last issue: 04.04.2023
Date of first issue: 07.01.2015

Serious eye damage/eye irritation

Causes serious eye damage.

Components:

Insulin Glargine:

Remarks : No data available

m-Cresol:

Species : Rabbit
Result : Irreversible effects on the eye

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:

Insulin Glargine:

Remarks : No data available

Germ cell mutagenicity

Not classified based on available information.

Components:

Insulin Glargine:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Remarks: Based on data from similar materials

Test Type: In vitro mammalian cell gene mutation test
Result: negative
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
Result: negative
Remarks: Based on data from similar materials

m-Cresol:

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: positive

Test Type: Bacterial reverse mutation assay (AMES)
Method: OECD Test Guideline 471
Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow
cytogenetic test, chromosomal analysis)

SAFETY DATA SHEET



Insulin Glargine Formulation

Version 5.1	Revision Date: 30.09.2023	SDS Number: 45327-00026	Date of last issue: 04.04.2023 Date of first issue: 07.01.2015
----------------	------------------------------	----------------------------	-------------------------------------------------------------------

Species: Mouse
Application Route: Ingestion
Method: OECD Test Guideline 475
Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Insulin Glargine:

Species	:	Rat
Exposure time	:	2 Years
NOAEL	:	0,455 mg/kg body weight
Result	:	negative
Species	:	Mouse
Exposure time	:	2 Years
NOAEL	:	0,455 mg/kg body weight
Result	:	negative

m-Cresol:

Species	:	Mouse, males
Application Route	:	Ingestion
Exposure time	:	105 weeks
Result	:	equivocal
Remarks	:	Based on data from similar materials
Species	:	Mouse, female
Application Route	:	Ingestion
Exposure time	:	106 - 107 weeks
Result	:	positive
Remarks	:	Based on data from similar materials
Carcinogenicity - Assessment	:	Weight of evidence does not support classification as a carcinogen

Reproductive toxicity

Not classified based on available information.

Components:

Insulin Glargine:

Effects on fertility	:	Test Type: Fertility/early embryonic development Species: Rat Application Route: Subcutaneous Fertility: NOAEL: 0,36 mg/kg body weight Result: No effects on fertility.
----------------------	---	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Test Type: Fertility/early embryonic development
Species: Rabbit
Application Route: Subcutaneous
Fertility: NOAEL: 0,072 mg/kg body weight
Result: No effects on fertility.

SAFETY DATA SHEET



Insulin Glargine Formulation

Version
5.1

Revision Date:
30.09.2023

SDS Number:
45327-00026

Date of last issue: 04.04.2023
Date of first issue: 07.01.2015

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Subcutaneous
Developmental Toxicity: NOAEL: 0,36 mg/kg body weight
Result: No effects on fetal development.

Species: Rabbit
Application Route: Subcutaneous
Developmental Toxicity: LOAEL: 0,072 mg/kg body weight
Result: Fetotoxicity.
Remarks: The mechanism or mode of action may not be relevant in humans.

m-Cresol:

Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on fetal development : Test Type: Prenatal development toxicity study (teratogenicity)
Species: Rat
Application Route: Ingestion
Result: negative

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

May cause damage to organs (Blood, Nervous system) through prolonged or repeated exposure if swallowed.

Components:

Insulin Glargine:

Routes of exposure : Ingestion
Target Organs : Blood, Nervous system
Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Insulin Glargine:

Species : Rat
NOAEL : 0,5 mg/kg
LOAEL : 1,5 mg/kg
Application Route : Subcutaneous
Exposure time : 30 d
Target Organs : Blood, Nervous system

m-Cresol:

SAFETY DATA SHEET



Insulin Glargine Formulation

Version 5.1 Revision Date: 30.09.2023 SDS Number: 45327-00026 Date of last issue: 04.04.2023 Date of first issue: 07.01.2015

Species : Rat
NOAEL : 150 mg/kg
Application Route : Ingestion
Exposure time : 13 Weeks
Method : OECD Test Guideline 408

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Insulin Glargine:

Inhalation : Target Organs: Blood
Symptoms: Hypoglycemia, Headache, Sweating, Tremors, Nausea

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

m-Cresol:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 8,6 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia pulex (Water flea)): > 99,5 mg/l
Exposure time: 48 h

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 1,35 mg/l
Exposure time: 32 d
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 1 mg/l
Exposure time: 21 d
Remarks: Based on data from similar materials

Persistence and degradability

Components:

m-Cresol:

Biodegradability : Result: Readily biodegradable.
Biodegradation: 90 %
Exposure time: 28 d
Method: OECD Test Guideline 301D

Bioaccumulative potential

Components:

m-Cresol:

SAFETY DATA SHEET



Insulin Glargine Formulation

Version 5.1 Revision Date: 30.09.2023 SDS Number: 45327-00026 Date of last issue: 04.04.2023
Date of first issue: 07.01.2015

Bioaccumulation : Species: Leuciscus idus (Golden orfe)
Bioconcentration factor (BCF): 17 - 20

Partition coefficient: n-octanol/water : log Pow: 1,96

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Argentina. Carcinogenic Substances and Agents Registry. : Not applicable

Control of precursors and essential chemicals for the preparation of drugs. : Not applicable

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

SAFETY DATA SHEET



Insulin Glargine Formulation

Version 5.1	Revision Date: 30.09.2023	SDS Number: 45327-00026	Date of last issue: 04.04.2023 Date of first issue: 07.01.2015
----------------	------------------------------	----------------------------	-------------------------------------------------------------------

IECSC : not determined

SECTION 16. OTHER INFORMATION

Revision Date : 30.09.2023
Date format : dd.mm.yyyy

Further information

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
AR OEL : Argentina. Occupational Exposure Limits
ACGIH / TWA : 8-hour, time-weighted average
AR OEL / CMP : TLV (Threshold Limit Value)

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a

SAFETY DATA SHEET



Insulin Glargine Formulation

Version
5.1

Revision Date:
30.09.2023

SDS Number:
45327-00026

Date of last issue: 04.04.2023
Date of first issue: 07.01.2015

guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AR / Z8